Arterial Spin-Labeling and MR Spectroscopy in the Differentiation of Gliomas

References

1. ↵
   Kaba SE, Kyritsis AP. Recognition and management of gliomas. Drugs 1997;53:235–44

   PubMedWeb of Science
2. ↵
   Davies E, Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group, Royal College of Physicians. Br J Neurosurg 1997;11:318–30

   CrossRefPubMedWeb of Science
3. ↵
   Hsu YY, Chang CN, Wie KJ, et al. Proton magnetic resonance spectroscopic imaging of cerebral gliomas: correlation of metabolite ratios with histopathologic grading. Chang Gung Med J 2004;27:399–407

   PubMed
4. ↵
   Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003;98:74–81

   PubMed
5. ↵
   Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002;44:656–66

   CrossRefPubMed
6. ↵
   Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204–12

   CrossRefPubMedWeb of Science
7. ↵
   Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919–26

   PubMedWeb of Science
8. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

   PubMedWeb of Science
9. ↵
   Sabatier J, Ibarrola D, Malet-Martino M, et al. [Brain tumors: interest of magnetic resonance spectroscopy for the diagnosis and the prognosis]. Rev Neurol (Paris) 2001;157:858–62

   PubMed
10. ↵
    Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449–58

    CrossRefPubMedWeb of Science
11. Cheng LL, Chang IW, Louis DN, et al. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998;58:1825–32

    Abstract/FREE Full Text
12. ↵
    McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794–802

    PubMedWeb of Science
13. ↵
    Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29–36

    CrossRefPubMedWeb of Science
14. ↵
    Wolf RL, Wang J, Wang S, et al. Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 2005;22:475–82

    CrossRefPubMed
15. ↵
    Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol 2005;72:261–65

    CrossRefPubMed
16. Magalhaes A, Godfrey W, Shen Y, et al. Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol 2005;12:51–57

    CrossRefPubMedWeb of Science
17. ↵
    Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000;50:215–26

    CrossRefPubMed
18. ↵
    Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222:715–21

    PubMedWeb of Science
19. ↵
    Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
20. ↵
    Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996;16:1236–49

    CrossRefPubMedWeb of Science
21. ↵
    Wang J, Zhang Y, Wolf RL, et al. Amplitude-modulated continuous arterial spin-labeling 3.0-T perfusion MR imaging with a single coil: feasibility study. Radiology 2005;235:218–28

    CrossRefPubMedWeb of Science
22. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [published erratum appears in AJNR Am J Neuroradiol 2004;25:B1]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
23. ↵
    Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–79

    CrossRefPubMedWeb of Science
24. ↵
    Kleihues P, Soylemezoglu F, Schauble B, et al. Histopathology, classification, and grading of gliomas. Glia 1995;15:211–21

    CrossRefPubMedWeb of Science
25. ↵
    Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001;159:779–86

    CrossRefPubMedWeb of Science
26. ↵
    Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523–32

    CrossRefPubMedWeb of Science
27. ↵
    Runge VM, Clanton JA, Price AC, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging 1985;3:43–55

    CrossRefPubMed
28. ↵
    Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
29. ↵
    Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002;58:111–17

    CrossRefPubMedWeb of Science
30. ↵
    von Deimling A, Louis DN, von Ammon K, et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277–79

    Abstract/FREE Full Text
31. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91–95

    CrossRefPubMedWeb of Science
32. Rosenberg JE, Lisle DK, Burwick JA, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996;13:2483–85

    PubMedWeb of Science
33. ↵
    Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175–90

    PubMedWeb of Science
34. ↵
    Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol 1997;34:61–78

    CrossRefPubMed
35. ↵
    Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593–603

    Abstract
36. ↵
    Hall WA, Martin A, Liu H, et al. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001;13:12–15

    CrossRefPubMed
37. ↵
    Michaelis T, Merboldt KD, Bruhn H, et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993;187:219–27

    PubMedWeb of Science
38. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47–52

    CrossRefPubMedWeb of Science
39. Nishizuka Y. Membrane phospholipid degradation and protein kinase C for cell signalling. Neurosci Res 1992;15:3–5

    PubMed
40. ↵
    Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413–39

    CrossRefPubMedWeb of Science
41. ↵
    Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21:357–66

    Abstract/FREE Full Text
42. ↵
    Folkman J. Tumor angiogenesis. Adv Cancer Res 1974;19:331–58

    PubMed
43. ↵
    Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88:2606–18

    CrossRefPubMedWeb of Science
44. ↵
    Kuesel AC, Sutherland GR, Halliday W, et al. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994;7:149–55

    PubMed
45. ↵
    Majós C, Alonso J, Aguilera C, et al. Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology 2002;225:556–66

    PubMed
46. ↵
    Likavcanová K, Dobrota D, Liptaj T, et al. In vitro study of astrocytic tumour metabolism by proton magnetic resonance spectroscopy. Gen Physiol Biophys 2005;24:327–35

    PubMedWeb of Science
47. ↵
    Lehnhardt FG, Bock C, Rohn G, et al. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 2005;18:371–82

    CrossRefPubMedWeb of Science
48. ↵
    Bouzier AK, Quesson B, Valeins H, et al. [1-(13)C]glucose metabolism in the tumoral and nontumoral cerebral tissue of a glioma-bearing rat. J Neurochem 1999;72:2445–55

    CrossRefPubMed
49. ↵
    Medina MA, Marquez J, Nunez de Castro I. Interchange of amino acids between tumor and host. Biochem Med Metab Biol 1992;48:1–7

    CrossRefPubMed
50. ↵
    Souba WW. Glutamine and cancer. Ann Surg 1993;218:715–28

    CrossRefPubMedWeb of Science
51. ↵
    Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383–91

    Abstract/FREE Full Text
52. ↵
    Majós C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003;13:582–91

    PubMed
53. ↵
    Hagberg G, Burlina AP, Mader I, et al. In vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi-dimensional classification. Magn Reson Med 1995;34:242–52

    PubMed
54. ↵
    Majós C, Julia-Sape M, Alonso J, et al. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol 2004;25:1696–704

    Abstract/FREE Full Text
55. ↵
    Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006;238:958–69

    CrossRefPubMedWeb of Science